Polio Immunization: Moving Forward

Presentations

DAY ONE - September 19, 2007

Welcome and Objectives, Roger Glass (Fogarty International Center) and Hugh Auchincloss (National Institute of Allergy and Infectious Diseases) (PDF)

Current Status of the Eradication Program, Bruce Aylward (World Heatlh Organization) (PDF)

Current Challenges to the Eradication Program, Jacob John (Christian Medical College, India) (PDF)

• The 4-Country Challenge to Polio Eradication, Jacob John (Christian Medical College, India) (PDF)
• Polio Update - Pakistan & Afghanistan, Tariq Bhutta (National Certification Committee on Eradication of Poliomyelitis) (PDF)
• Polio Eradication - Focus on India, Naveen Thacker (Indian Academy of Pediatrics) (PDF)
• Polio Eradication in Nigeria - Why, When and How, Oyewale Tomori (Redeemer's University, Nigeria) (PDF)

• Challenges to Polio Eradication in Africa, Jean-Jacques Muyembe Tamfun (Institut National de Recherche Biomédicale), Francis Nkrumah (Noguchi Memorial Institute of Medical Research, Ghana) (PDF)

OPV, Vadim Agol (Moscow State University) (PDF)

• Co-circulation and Evolution of Polioviruses and Species C Enteroviruses in Madagascar, Francis Delperoux (Institut Pasteur) (PDF)
• OPV: aVDPV Strains Detected at KTL, Helsinki, Tapani Hovi (National Public Health Institute, Finland) (PDF)
• Benefits and Risks of OPV Use, Olen Kew (US Centers for Disease Control and Prevention) (PDF)
• Phil Minor, (National Institute for Biologicals Standards and Control) (PDF)
• Polioviruses in the Environment in Israel: Implications for the Global Poliomyelitis Eradication Initiative, Lester Shulman (Public Health Services, Israel Ministry of Health) (PDF)

IPV, John Modlin (Dartmouth Medical School) (PDF)

• IPV in Developing Countries, Neal Halsey (Johns Hopkins Bloomberg School of Public Health) (PDF)
• Transmission of Polioviruses in IPV Immunized Populations, Tapani Hovi (National Public Health Institute, Finland) (PDF)
• Report of Expert Consultations on Potential Use of IPV in Interrupting WPV Transmission in Western UP, India, Lalit Kant (Indian Council of Medical Research) (PDF)
• Immunogenicity of IPV-Containing Vaccines in Tropical Countries: Three Decades of Experience, Emmanuel Vidor (Sanofi pasteur) (PDF)

Risk/Benefit Assessments, Peter Wright (Vanderbilt Medical Center) (PDF)

• Improving Data Sets with Regard to the Biology and Neurotrophic Potential of Enteroviruses other than Polio, Raul Andino (University of California, San Francisco) (PDF)
• Replication Fidelity Based Vaccines: A Novel Approach to Polio Vaccines, Raul Andino (University of California, San Francisco) (PDF)
• Risks After "Eradication" (of wild virus)...and What Do They Mean?, Paul Fine (London School of Hygiene and Tropical Medicine) (PDF)
• Polio Eradication: What We Can Learn from an Analysis?, Kimberly Thompson, Harvard School of Public Health (PDF)

Current and Future Immunization Policy Considerations, Walter Dowdle (The Task Force for Child Survival and Development)

• What Affects Whether or Not a Drug-Resistant Virus Escapes the Cell in Which it Arose?, Karla Kirkegaard (Stanford University) (PDF)
• The Controversy: Control or Eradication, Mark Miller (Fogarty International Center) (PDF)
• Strategic Planning for the Post-Eradication Era of Poliomyelitis, Roland Sutter (World Health Organization) (PDF)
• Global Action Plan to Minimize Poliovirus Facility - Associated Risk in the Post-Eradication/Post-OPV Era, Chris Wolff (World Health Organization, Global Polio Eradication Initiative) (PDF)

DAY TWO - September 20, 2007

Current Research Activities, Konstantin Chumakov (US Food and Drug Administration) (PDF)

• Sabin IPV Process Development, Wilfried Bakker (Netherlands Vaccine Institute) (PDF)
• Potential for Polio Antiviral Drugs, Marc Collet (ViroDefense, Inc.) (PDF)
• New Strains for Polio Vaccines, Andrew Macadam (National Institute for Biological Standards and Control, UK) (PDF)
• Update on Major IPV Initiatives, Mark Pallansch (US Centers for Disease Control and Prevention) (PDF)
• GSK Biologicals Perspectives on the Future IPV, Isabelle Pierard, Michele Duchene (GlaxoSmithKline) (PDF)
• Development of Sabin-Inactivated Poliovirus Vaccine, Bunsiti Simuzu (Japan Poliomyelitis Research Insitute) (PDF)
• Randomized Trial of Inactivated Polio Vaccine Schedules in Guatemala, Neal Halsey (Johns Hopkins Bloomberg School of Public Health) (PDF)

Future Research and Control Strategies, Sam Katz (Duke University) (PDF)

• Poliovirus Immunization: Future Directions, Ellie Ehrenfeld (National Institute of Allergy and Infectious Diseases) (PDF)
• Future Directions, D.A. Henderson (University of Pittsburgh Medical Center) (PDF)
• Achieving and Maintaining Polio Eradication, Walter Orenstein (Emory University School of Medicine) (PDF)
• The Place of IPV in Polio Vaccination of Developing Countries, Stanley Plotkin (Sanofi pasteur, University of Pennsylvania) (PDF)

Conclusions and Discussion, Vadim Agol

back to top